drugset
drugset / Trial / NCT06829199

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

NCT06829199 ↗

Phase 2 Withdrawn Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.

Timeline

Start
2025-03-26
Primary completion
2029-01-18
Completion
2031-03-18

Outcome

Outcome not reported

Stopped (Enrollment): “Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Boserolimab Monoclonal antibody 30 mg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Capecitabine Small molecule 1250 mg/m2 Oral
Background Carboplatin Small molecule 1.5 unknown Intravenous
Background Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Background Epirubicin Small molecule 90 mg/m2 Intravenous
Background Olaparib Small molecule 300 mg Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous
Background Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Pembrolizumab Monoclonal antibody 400 mg Intravenous

Indications

triple-negative breast carcinoma